Shares of Accelerate Diagnostics Inc. (NASDAQ:AXDX) were up 4.6% on Monday . The stock traded as high as $17.55 and last traded at $17.55, with a volume of 301,732 shares. The stock had previously closed at $16.78.

Several analysts recently weighed in on AXDX shares. BTIG Research reissued a “buy” rating and set a $26.00 price target on shares of Accelerate Diagnostics in a report on Sunday, May 15th. Piper Jaffray Cos. reissued a “buy” rating on shares of Accelerate Diagnostics in a report on Monday, April 11th. Finally, JPMorgan Chase & Co. started coverage on Accelerate Diagnostics in a report on Thursday, March 24th. They set an “overweight” rating and a $17.00 price target for the company.

The company’s market capitalization is $898.88 million. The firm’s 50-day moving average is $14.61 and its 200 day moving average is $14.13.

In other news, Director Jack W. Schuler bought 90,147 shares of the firm’s stock in a transaction that occurred on Thursday, June 30th. The stock was bought at an average price of $13.95 per share, with a total value of $1,257,550.65. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jack W. Schuler bought 88,316 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were purchased at an average cost of $14.69 per share, with a total value of $1,297,362.04. The disclosure for this purchase can be found here.

A number of large investors have recently bought and sold shares of AXDX. Neuberger Berman Group LLC boosted its stake in Accelerate Diagnostics by 124.0% in the fourth quarter. Neuberger Berman Group LLC now owns 48,500 shares of the company’s stock worth $1,042,000 after buying an additional 26,850 shares during the last quarter. Birchview Capital LP boosted its stake in Accelerate Diagnostics by 4.3% in the fourth quarter. Birchview Capital LP now owns 2,155,795 shares of the company’s stock worth $46,328,000 after buying an additional 88,235 shares during the last quarter. Finally, Tekla Capital Management LLC boosted its stake in Accelerate Diagnostics by 83.0% in the fourth quarter. Tekla Capital Management LLC now owns 264,625 shares of the company’s stock worth $5,687,000 after buying an additional 120,000 shares during the last quarter.

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.